Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study | Zendy

Jessica Cusato | Zendy; Amedeo De Nicolò | Zendy; Lucio Boglione | Zendy; F. Favata | Zendy; Alessandra Ariaudo | Zendy; Simone Mornese Pinna | Zendy; Federica Guido | Zendy; Valeria Avataneo | Zendy; Chiara Carcieri | Zendy; Giuseppe Cariti | Zendy; Giovanni Di Perri | Zendy; Antonio D’Avolio | Zendy

Open Access

Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study

Author(s) -

Jessica Cusato,

Amedeo De Nicolò,

Lucio Boglione,

F. Favata,

Alessandra Ariaudo,

Simone Mornese Pinna,

Federica Guido,

Valeria Avataneo,

Chiara Carcieri,

Giuseppe Cariti,

Giovanni Di Perri,

Antonio D’Avolio

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx237

Subject(s) - daclatasvir , medicine , pharmacogenetics , pharmacology , oncology , single nucleotide polymorphism , gastroenterology , genotype , genetics , gene , biology , virology , hepatitis c virus , virus , ribavirin

Daclatasvir is an inhibitor of HCV non-structural 5A protein and is a P-glycoprotein substrate. Pharmacogenetics has had a great impact on previous anti-HCV therapies, particularly considering the association of IL-28B polymorphisms with dual therapy outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research